Literature DB >> 1430231

Immune complex processing in patients with systemic lupus erythematosus. In vivo imaging and clearance studies.

K A Davies1, A M Peters, H L Beynon, M J Walport.   

Abstract

Abnormal processing of immune complexes (IC) may be important in the pathogenesis of systemic lupus erythematosus (SLE). The clearance of large soluble IC (comprising hepatitis B surface antigen (HBsAg)/anti-HBsAg) radiolabeled with 123I was examined in 12 normal subjects and 10 patients with SLE. IC localization was analyzed by static and dynamic gamma-scintigraphy. Initial IC clearance from blood was more rapid in patients (median t1/2 = 2.15 min) than normals (median t1/2 = 5.15 min) due to more rapid uptake in the liver. However, in the SLE group, up to 12% of complexes were released from the liver after 30-50 min. Splenic uptake of immune complexes was reduced in the patients and there was reduced ability to retain IC in this organ. Plasma complement levels and erythrocyte complement receptor type 1 numbers were reduced in the patients, resulting in defective opsonization of IC and reduced red cell binding in vivo. These observations support the hypothesis that IC handling is abnormal in SLE.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1430231      PMCID: PMC443274          DOI: 10.1172/JCI116090

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  Guinea-worm Arthritis of Knee Joint.

Authors:  C R Reddy; M Sivaramappa
Journal:  Br Med J       Date:  1968-01-20

2.  The generation of memory cells. I. The role of C3 in the generation of B memory cells.

Authors:  G G Klaus; J H Humphrey
Journal:  Immunology       Date:  1977-07       Impact factor: 7.397

3.  A simplified method of quantitating organ uptake using a gamma camera.

Authors:  M J Myers; J P Lavender; J B de Oliveira; A Maseri
Journal:  Br J Radiol       Date:  1981-12       Impact factor: 3.039

4.  Primate erythrocyte-immune complex-clearing mechanism.

Authors:  J B Cornacoff; L A Hebert; W L Smead; M E VanAman; D J Birmingham; F J Waxman
Journal:  J Clin Invest       Date:  1983-02       Impact factor: 14.808

5.  Use of N-bromosuccinimide for the iodination of proteins for radioimmunoassay.

Authors:  P Reay
Journal:  Ann Clin Biochem       Date:  1982-03       Impact factor: 2.057

6.  Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways.

Authors:  J A Schifferli; P Woo; D K Peters
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

7.  A serial study of splenic reticuloendothelial system Fc receptor functional activity in systemic lupus erythematosus.

Authors:  M I Hamburger; T J Lawley; R P Kimberly; P H Plotz; M M Frank
Journal:  Arthritis Rheum       Date:  1982-01

8.  NIH Conference: Immunoglobulin G Fc receptor-mediated clearance in autoimmune diseases.

Authors:  M M Frank; T J Lawley; M I Hamburger; E J Brown
Journal:  Ann Intern Med       Date:  1983-02       Impact factor: 25.391

9.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

10.  Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus.

Authors:  K Iida; R Mornaghi; V Nussenzweig
Journal:  J Exp Med       Date:  1982-05-01       Impact factor: 14.307

View more
  34 in total

1.  Anti-cytokeratin antibodies in sera of the patients with autoimmune hepatitis.

Authors:  M Murota; M Nishioka; J Fujita; N Dobashi; F Wu; Y Ohtsuki; S Hojo; J Takahara; S Kuriyama
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

2.  Defective waste disposal: does it induce autoantibodies in SLE?

Authors:  Peter J Charles
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

Review 3.  Complement in the immunopathogenesis of rheumatic disease.

Authors:  Gunnar Sturfelt; Lennart Truedsson
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

4.  Markers of childhood lupus nephritis indicating disease activity.

Authors:  Monika Edelbauer; Sudhir Kshirsagar; Magdalena Riedl; Dieter Haffner; Heiko Billing; Burkhard Tönshoff; Sophia Ross; Jörg Dötsch; Oliver Amon; Henry Fehrenbach; Christian Steuber; Antje Beissert; Josef Hager; Gottfried Wechselberger; Lutz T Weber; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2010-12-22       Impact factor: 3.714

Review 5.  Activating and inhibitory FcgammaRs in autoimmune disorders.

Authors:  Falk Nimmerjahn
Journal:  Springer Semin Immunopathol       Date:  2006-10-01

6.  Systemic lupus erythematosus serum deposits C4d on red blood cells, decreases red blood cell membrane deformability, and promotes nitric oxide production.

Authors:  Ionita C Ghiran; Mark L Zeidel; Sergey S Shevkoplyas; Jennie M Burns; George C Tsokos; Vasileios C Kyttaris
Journal:  Arthritis Rheum       Date:  2011-02

Review 7.  B cells in glomerulonephritis: focus on lupus nephritis.

Authors:  Menna R Clatworthy; Kenneth G C Smith
Journal:  Semin Immunopathol       Date:  2007-10-18       Impact factor: 9.623

Review 8.  Gene-expression profiling in rheumatic disease: tools and therapeutic potential.

Authors:  Jason W Bauer; Hatice Bilgic; Emily C Baechler
Journal:  Nat Rev Rheumatol       Date:  2009-05       Impact factor: 20.543

9.  Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms.

Authors:  K Manger; R Repp; M Jansen; M Geisselbrecht; R Wassmuth; N A C Westerdaal; A Pfahlberg; B Manger; J R Kalden; J G J van de Winkel
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

10.  The anti-lipid A antibody HA-1A binds to rough gram-negative bacteria, fixes complement and facilitates binding to erythrocyte CR1 (CD35).

Authors:  M Tonoli; K A Davies; P J Norsworthy; J Cohen; M J Walport
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.